Skip to main content

Physician Search

 


Displaying 1 - 1 of 1

A Phase I / II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Lung

This is a multicenter, non-randomized, open-label, phase I / II study to evaluate the safety and tolerability of AMG 510 plus MVASI in subjects with advanced KRAS p.G12C mutant non-small cell lung cancer (NSCLC) with small, untreated brain metastases.
Lung
I/II
Iams, Wade
NCT05180422
VICCTHOP21115